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Previewsthe apical domain away from the apically
localized neuronal fate determinant and
thus allow this cell to remain proliferative.
Further investigation should provide
fascinating insights on how Foxp genes
control the fate of neuroepithelial NPCs
and contribute to the generation of other
types of progenitors found in mammalian
cortices.
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In this issue of Neuron, work from Moughamian and Holzbaur (2012) and Lloyd et al. (2012) reveals a role for
p150 in initiation of retrograde transport at synaptic terminals. These studies also suggest how mutations of
p150’s CAP-Gly domain lead to both Perry syndrome and HMN7B disease.Although most cells are measured in
microns, neurons, especially peripheral
neurons, can be a meter long and there-
fore make extreme demands on our
molecular motors. Small wonder that
mutations in ubiquitous motor proteins
give rise to specifically neurological dis-
eases. Two such diseases, Perry syn-
drome and the distal hereditary motor
neuropathy 7B (HMN7B), are examples
of that phenomenon and their cell biolog-
ical basis has been examined by two
papers in this issue of Neuron (Mougha-
mian and Holzbaur, 2012; Lloyd et al.,
2012). Although their symptoms are quite
different, both diseases are caused by
mutations in the same domain of the dy-
nactin subunit p150Glued. By approachingthe function of this domain in Drosophila
neurons and mouse dorsal root ganglion
(DRG) neurons, the present studies illumi-
nate the function of p150Glued in axonal
transport.
Axonal microtubules are uniformly
polarized with their plus ends away from
the soma. Two classes of motor, kinesins
and cytoplasmic dynein, move along
these microtubule tracks to transport
cargo between the soma and nerve termi-
nals. Retrograde, minus-end-directed
transport is performed by dynein. Two
important functions of retrograde trans-
port are escorting aggregated/misfolded
proteins back to the soma for degradation
(Johnston et al., 2002) and communi-
cating synaptic and trophic signals tothe soma to regulate gene expression
(reviewed by Cosker et al., 2008). The
dynein motors are multisubunit com-
plexes, and much of the complex remains
poorly understood. Moreover, dynein
does not act alone; it acts in a complex
with a second multimeric protein as-
sembly known as dynactin. The largest
subunit of dynactin is p150, the mamma-
lian homolog of the Drosophila Glued
gene (Holzbaur et al., 1991). Dynactin is
mainly thought to be required for attach-
ing cargo to dynein with p150 forming
the dynein-dynactin link (Karki and Holz-
baur, 1995; Vaughan and Vallee, 1995).
Additional dynein-independent functions
of p150 have been reported that involve
organizing microtubule arrays and74, April 26, 2012 ª2012 Elsevier Inc. 211
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Figure 1. The CAP-Gly Domain of p150 Is Required for Initiation of Dynein Loading at Plus
Ends
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Previewsanchoring microtubules at the centro-
some (Askham et al., 2002;Quintyne
et al., 1999).
The cytoskeletal functions of p150
rely on its N-terminal, cytoskeleton-asso-
ciated protein glycine-rich (CAP-Gly) do-
main (Figure 1A). Those interactions
suggested that p150 anchors dynein to
microtubules and thereby increases
processivity—the number of consecutive
steps a motor takes before falling off
the microtubules. Purified dynein was
much less processive in vitro when either
p150 was absent or the CAP-Gly domain
was inhibited (Ross et al., 2006, and
references therein). In vivo, however,
dynein’s processivity was unperturbed
when p150’s CAP-Gly domain was
deleted (Kim et al., 2007). What then is
the purpose of p150s CAP-Gly domain?
One possibility was that it was required
only at the plus ends of microtubules and
not for processivity along their tracks. A
small population of p150 localizes to212 Neuron 74, April 26, 2012 ª2012 Elseviertheplus ends, andp150splus-endbinding
is regulated by phosphorylation of a serine
within the CAP-Gly domain (Vaughan
et al., 2002).Moreover, p150directly inter-
acts with the plus-end binding proteins
EB1, EB3, and CLIP-170 (Lansbergen
et al., 2004; Ligon et al., 2003). In this issue
of Neuron, both Moughamian and Holz-
baur (2012) andLloydet al. (2012) examine
the requirement of the CAP-Gly domain in
retrograde axonal transport. Knockdown
of p150 in both fly and mouse neurons
disrupted axonal transport and provided
systems in which to restore a deleted
p150. Both groups report that wild-type
p150 and p150 lacking the CAP-Gly
domain (ΔCAP-Gly) could equally rescue
much of the p150 knockdown phenotype;
the CAP-Gly domain was not required for
axonal transport or dynein processivity.
However, the large accumulations of
p150 that normally occur at the plus
ends of wild-type axons, in tips of distal
neurites or in terminal synaptic boutons,Inc.were dependent on the presence of the
CAP-Gly domain and, at least in the DRG
neurons, required EB1 and EB3. They
hypothesized that p150 might act in these
neurite tips to recruit dynein and thereby
initiate retrograde transport. Retrograde
flux, or the net movement of cargo from
the plus end to the soma, was therefore
examined by fluorescently labeling lyso-
somes in DRG neurons and endosomes
in the fly. By photobleaching a region
close to the neurite tip and then watching
the transit of those cargoes through the
bleached region, both groups observed
that, in the absence of CAP-Gly domain,
these organelles were not leaving the
endings in appropriate numbers, although
they were correctly delivered to the distal
tips. Promoting the initiation of retrograde
transport represents a new neuronal
function for p150s CAP-Gly domain.
If this is the main function of the
CAP-Gly domain and anterograde trans-
port is unaffected, one would expect
distal accumulations of dynein and its
cargo. In fact, Lloyd et al. (2012) noticed
gross accumulations of endosome com-
ponents, neuronal membranes, and
dynein in the distal boutons of fly neurons
when the CAP-Gly domain was lacking.
Moughamian and Holzbaur (2012) also
looked for such accumulations in DRG
neurons but did not see them. This pheno-
typic distinction is a curious difference
between the studies but may not reflect
a species difference in the function of
the domain so much as the conditions
studied. The fly neuromuscular junction
has differentiated terminal boutons in
which the cargo piles up, but the ongoing
axonal growth in DRG cultures may have
allowed dynein and its cargoes to be
dispersed as the neurite extended. Sig-
nificant differences may nonetheless
exist in the manner in which cells handle
the initiation of retrograde transport. In
mammalian neurons, although p150 is
enriched at plus ends, little dynein accu-
mulates. p150 at the plus ends may
capture and rapidly tether arriving dynein
for the immediate initiation of cargo
loading and retrograde transport. How-
ever, in fungi, not just p150, but all of the
dynactin/dynein complex and LIS1 are
enriched at hyphal plus end tips through
an interaction of the EB1-like fungal
protein, Peb1, and p150s CAP-Gly
domain. In those cells, dynactin and
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Previewsdynein are delivered but are not released
for retrograde transport until triggered by
the separate delivery of early endosomes
(Lenz et al., 2006). Thus, some cell types
may elect only to keep dynactin on hand
at the plus end (through the EB1/EB3/
p150 interaction; Figure 1B), while other
cells store dynein there as well. The
mechanism regulating initiation of motor
activity will likely differ between cell types.
Both the Perry syndrome and HMN7B
mutations occur within the CAP-Gly do-
main of p150 (Figure 1A), and both
are autosomal-dominant diseases, but
whereas HMN7B, like amyotrophic lateral
sclerosis, causes degeneration specifi-
cally of motor neurons, Perry syndrome
most prominently affects the substania
nigra and brainstem and causes Parkin-
sonian symptoms. To study Perry syn-
drome and HMN7B, both groups
expressed transgenes containing the
pathogenic point mutations. By exam-
ining retrograde flux, both groups found
that the disease mutations perturbed
the ability of p150 to associate with
microtubules and observed problems
with the initiation of retrograde transport.
Why then do they cause such different
symptoms in humans? Both groups noted
that protein aggregates formed when
these alleles were expressed, but that
this tendency, particularly in neurons,
was more pronounced for the HMN7B
mutations. This distinction correlates
with the histopathology of affected indi-
viduals. Potentially more enlightening,
however, were biochemical studies by
Moughamian and Holzbaur (2012).
Although both Perry and HMN7B muta-
tions allow p150 to dimerize and incorpo-
rate into the dynactin complex, the
HMN7B mutation alone prevents the dy-
nactin complex from binding to dynein.
Whereas the Perry syndrome mutations
lie on the surface, in or very close to
the site of microtubule and EB1 binding,
the HMN7B mutation is in the core of the
domain and likely to interfere with its
folding. Thus, although CAP-Gly domain
is far from the known dynein-interactingportion of p150, the likely severe misfold-
ing of this domain may promote its
aggregation and prevent proper incorpo-
ration into the motor. These biochemical
changes are reflected in phenotypic
differences observed in these studies.
In DRG neurons, the HMN7B mutation
seriously perturbed both anterograde
and retrograde transport and decreased
the processivity of cargo, as might be
expected if dynein was operating without
its dynactin partner. This defect did not
arise when the Perry syndrome allele
was expressed. In Drosophila, only the
HMN7B mutation caused dynein heavy
chain to accumulate substantially in the
terminal boutons, as might be expected
if the dynein motor is bereft of dynactin
association. Thus, HMN7B may be
understood as a dominant negative that
compromises the entire function of the
dynactin complex, while Perry syndrome
selectively impairs retrograde initiation
while leaving other functions of dynactin
intact.
Of course several questions remain un-
answered. Most particularly, we do not
yet know why the broader disruption of
dynactin function is most manifest in the
substantia nigra and brainstem while the
motor neurons are most sensitive to
the subtler impairment of retrograde
initiation. That puzzle vexes most discus-
sions of neurodegenerative disease. The
specificities may arise from differences
in the dependence of neuronal subtypes
on retrograde transport of survival sig-
nals or in their sensitivity to protein
aggregates. Mechanistic questions also
remain: how does p150 regulate transport
at terminal boutons? Does the phosphor-
ylation of p150s CAP-Gly domain trigger
the release of the entire dynein/dynactin
complex from the plus ends? Several
microtubule plus end-binding proteins
(EB1, EB3, CLIP-170, and LIS1) may
regulate initiation of transport in conjunc-
tion with p150 perhaps by allowing p150
to bind plus ends, to capture dynein, or
even to be released from the plus ends
once the dynactin/dynein complex isNeuronformed. The present papers, however,
by examining rigorously the cell biology
of these mutations and the CAP-Gly
domain itself have opened doors to
further understanding retrograde move-
ment and stress the importance of main-
taining a finely tuned axonal transport
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